down arrow

Haemonetics Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4050241003
USD
83.81
1.9 (2.32%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

81.5084.19

52 Week

47.3185.00
Valuation
Technical
Day's Volume

CASH

647.66 k

Shareholding (Mar 2025)

FII

14.09%

Held by 153 FIIs

DII

32.83%

Held by 59 DIIs

Promoter

0.01%

How big is Haemonetics Corp.?

22-Jun-2025

As of Jun 18, Haemonetics Corp. has a market capitalization of 3,315.03 million, with net sales of 1,360.82 million and a net profit of 167.67 million over the latest four quarters. Shareholder's funds are 820.84 million, and total assets are 2,450.95 million.

As of Jun 18, Haemonetics Corp. has a market capitalization of 3,315.03 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,360.82 million and a net profit of 167.67 million for the latest four quarters.<BR><BR>As of Mar 25, the shareholder's funds amounted to 820.84 million, while total assets were reported at 2,450.95 million.

Read More

What does Haemonetics Corp. do?

22-Jun-2025

Haemonetics Corporation is a healthcare company specializing in blood processing, handling, and analysis products. As of March 2025, it reported net sales of $331 million and a net profit of $58 million, with a market cap of approximately $3.32 billion.

Overview: <BR>Haemonetics Corporation is a healthcare company that provides products for the processing, handling, and analysis of blood, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 331 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 58 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,315.03 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.13 <BR>Return on Equity: 18.58% <BR>Price to Book: 4.04<BR><BR>Contact Details: <BR>Address: 125 SUMMER STREET, BOSTON MA: 02110 <BR>Tel: ['1 781 8487100', '1 781 3569763'] <BR>Website: https://www.haemonetics.com

Read More

Who are in the management team of Haemonetics Corp.?

22-Jun-2025

As of March 2022, Haemonetics Corp.'s management team includes CEO Christopher Simon and several independent directors, including Richard Meelia (Chairman), Robert Abernathy, Catherine Burzik, Michael Coyle, Charles Dockendorff, and Mark Kroll.

As of March 2022, the management team of Haemonetics Corp. includes the following individuals:<BR><BR>- Mr. Richard Meelia, who serves as the Independent Chairman of the Board.<BR>- Mr. Christopher Simon, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Robert Abernathy, who is an Independent Director.<BR>- Ms. Catherine Burzik, who is also an Independent Director.<BR>- Mr. Michael Coyle, another Independent Director.<BR>- Mr. Charles Dockendorff, who serves as an Independent Director.<BR>- Dr. Mark Kroll, who is also an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Mr. Christopher Simon at the helm as CEO.

Read More

Is Haemonetics Corp. technically bullish or bearish?

20-Sep-2025

As of August 15, 2025, Haemonetics Corp. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, moving averages, and underperformance against the S&P 500, with year-to-date returns of -34.49% compared to the index's 12.22%.

As of 15 August 2025, the technical trend for Haemonetics Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators: the MACD is bearish on both weekly and monthly time frames, Bollinger Bands are bearish, and moving averages are also bearish on a daily basis. The KST and Dow Theory both reflect bearish sentiment on weekly and monthly scales. Additionally, the OBV shows a mildly bearish stance. <BR><BR>Haemonetics has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -34.49% compared to the S&P 500's 12.22%, and a 1-year return of -32.35% versus 17.14% for the index.

Read More

Is Haemonetics Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Haemonetics Corp. is undervalued with a P/E ratio of 22 and an attractive valuation grade, despite a year-to-date return of -35.63%, indicating potential for recovery compared to the S&P 500's gain of 13.30%.

As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company is currently undervalued, supported by a P/E ratio of 22, an EV to EBITDA of 13.04, and a PEG ratio of 8.36. In comparison, its peers show more favorable valuations, with Haemonetics' P/E ratio significantly lower than Masimo Corp. at 179.74 and Bio-Rad Laboratories, Inc. at 16.20.<BR><BR>Despite its attractive valuation, Haemonetics has underperformed against the S&P 500, with a year-to-date return of -35.63% compared to the index's gain of 13.30%. This stark contrast in performance highlights the potential for recovery and value realization in Haemonetics Corp.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.96

 
2

Poor long term growth as Net Sales has grown by an annual rate of 7.32% and Operating profit at 8.03% over the last 5 years

 
3

Flat results in Jun 25

4

With ROCE of 12.30%, it has a attractive valuation with a 2.47 Enterprise value to Capital Employed

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,606 Million (Small Cap)

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.06

stock-summary
Return on Equity

18.06%

stock-summary
Price to Book

2.95

Revenue and Profits:
Net Sales:
321 Million
(Quarterly Results - Jun 2025)
Net Profit:
34 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
54.97%
0%
54.97%
6 Months
20.31%
0%
20.31%
1 Year
0.36%
0%
0.36%
2 Years
0.62%
0%
0.62%
3 Years
-2.7%
0%
-2.7%
4 Years
58.82%
0%
58.82%
5 Years
-27.53%
0%
-27.53%

Haemonetics Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Haemonetics Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, with its stock price at $68.36. Over the past year, the company has faced challenges, posting a -21.00% return, contrasting with the S&P 500's 12.65% gain. Key financial metrics indicate a competitive position despite stock volatility.

Read More

Is Haemonetics Corp. overvalued or undervalued?

As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company is currently undervalued, supported by a P/E ratio of 22, an EV to EBITDA of 13.04, and a PEG ratio of 8.36. In comparison, its peers show more favorable valuations, with Haemonetics' P/E ratio significantly lower than Masimo Corp. at 179.74 and Bio-Rad Laboratories, Inc. at 16.20. Despite its attractive valuation, Haemonetics has underperformed against the S&P 500, with a year-to-date return of -35.63% compared to the index's gain of 13.30%. This stark contrast in performance highlights the potential for recovery and value realization in Haemonetics Corp....

Read More
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Haemonetics Corp. has recently adjusted its valuation, showcasing a P/E ratio of 22 and a price-to-book value of 4.12. The company demonstrates a competitive position within the Pharmaceuticals & Biotechnology sector, particularly when compared to peers like Masimo Corp., Bio-Rad Laboratories, and Lantheus Holdings.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
7.32%
EBIT Growth (5y)
8.03%
EBIT to Interest (avg)
8.96
Debt to EBITDA (avg)
2.49
Net Debt to Equity (avg)
1.13
Sales to Capital Employed (avg)
0.69
Tax Ratio
20.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
10.56%
ROE (avg)
14.77%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
4.12
EV to EBIT
20.06
EV to EBITDA
13.04
EV to Capital Employed
2.47
EV to Sales
3.17
PEG Ratio
8.36
Dividend Yield
NA
ROCE (Latest)
12.30%
ROE (Latest)
18.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 113 Schemes (52.28%)

Foreign Institutions

Held by 153 Foreign Institutions (14.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -2.78% vs -5.14% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -41.38% vs 54.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "321.40",
          "val2": "330.60",
          "chgp": "-2.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "83.90",
          "val2": "79.70",
          "chgp": "5.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.90",
          "val2": "16.20",
          "chgp": "-136.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "34.00",
          "val2": "58.00",
          "chgp": "-41.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "171.60%",
          "val2": "155.70%",
          "chgp": "1.59%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 3.95% vs 12.01% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 42.60% vs 1.91% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,360.80",
          "val2": "1,309.10",
          "chgp": "3.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "337.90",
          "val2": "305.40",
          "chgp": "10.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.90",
          "val2": "16.50",
          "chgp": "-40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.10",
          "val2": "-43.80",
          "chgp": "95.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "167.70",
          "val2": "117.60",
          "chgp": "42.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "163.40%",
          "val2": "159.00%",
          "chgp": "0.44%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
321.40
330.60
-2.78%
Operating Profit (PBDIT) excl Other Income
83.90
79.70
5.27%
Interest
4.10
0.00
Exceptional Items
-5.90
16.20
-136.42%
Consolidate Net Profit
34.00
58.00
-41.38%
Operating Profit Margin (Excl OI)
171.60%
155.70%
1.59%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -2.78% vs -5.14% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -41.38% vs 54.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
1,360.80
1,309.10
3.95%
Operating Profit (PBDIT) excl Other Income
337.90
305.40
10.64%
Interest
9.90
16.50
-40.00%
Exceptional Items
-2.10
-43.80
95.21%
Consolidate Net Profit
167.70
117.60
42.60%
Operating Profit Margin (Excl OI)
163.40%
159.00%
0.44%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 3.95% vs 12.01% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 42.60% vs 1.91% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Haemonetics Corp. stock-summary
stock-summary
Haemonetics Corp.
Pharmaceuticals & Biotechnology
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
Company Coordinates stock-summary
Company Details
125 SUMMER STREET , BOSTON MA : 02110
stock-summary
Tel: 1 781 84871001 781 3569763
stock-summary
https://www.haemonetics.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."